US Broker Ratings

Alpha Tau Medical Ltd. (DRTS) Stock Analysis: Biotechnology Innovator with 22.59% Upside Potential

Alpha Tau Medical Ltd. (NASDAQ: DRTS), an innovative player in the biotechnology sector, has been capturing the attention of investors with its pioneering approach to cancer treatment. With a market..

ExxonMobil Holdings Corporation (XOM) Stock Analysis: Navigating a Robust Revenue Growth and Projected Upside

ExxonMobil Holdings Corporation (NYSE: XOM) stands as a formidable entity in the energy sector, with its operations spanning the globe. As an integrated oil and gas giant, the company engages..

Nyxoah SA (NYXH) Stock Analysis: Unpacking the 220% Potential Upside for This Medical Device Pioneer

In the dynamic world of healthcare innovation, Nyxoah SA (NASDAQ: NYXH) emerges as a notable player, particularly in the medical devices industry. Headquartered in Mont-Saint-Guibert, Belgium, the company is at..

ZoomInfo Technologies Inc. (GTM) Stock Analysis: Evaluating the 17.88% Potential Upside in a Challenging Market

ZoomInfo Technologies Inc. (NASDAQ: GTM), a key player in the software application industry, operates at the intersection of technology and business intelligence. With a market cap of $1.14 billion, ZoomInfo..

Sprout Social, Inc (SPT) Stock Analysis: Navigating Growth with a 4.92% Potential Upside

Sprout Social, Inc (NASDAQ: SPT) stands as a notable player in the technology sector, specifically within the software application industry, offering a comprehensive suite of social media management tools for..

SANUWAVE Health, Inc. (SNWV) Stock Analysis: Navigating the Challenges of a Volatile 52-Week Range

SANUWAVE Health, Inc. (NASDAQ: SNWV) stands at the intersection of innovation and challenge within the medical device sector. With a focus on regenerative medicine, SANUWAVE is pioneering noninvasive ultrasound technology..

Grab Holdings Limited (GRAB) Stock Analysis: Unpacking the 80.66% Potential Upside

Grab Holdings Limited (NASDAQ: GRAB), the technology juggernaut behind Southeast Asia’s leading superapp, presents an intriguing investment opportunity with a staggering potential upside of 80.66%. With its diverse portfolio, ranging..

Viant Technology Inc. (DSP) Stock Analysis: Exploring a 58.67% Potential Upside Driven by Strong Revenue Growth

Viant Technology Inc. (NASDAQ: DSP), a key player in the technology sector’s software application industry, is currently capturing investor attention with its robust revenue growth and significant potential upside. Based..

Anbio Biotechnology (NNNN): Investor Outlook on a Rapidly Growing IVD Player with 73.9% Revenue Surge

Anbio Biotechnology (NNNN), a burgeoning player in the healthcare sector, has captured the attention of investors with its impressive revenue growth of 73.9%. Based in Frankfurt am Main, Germany, Anbio..

AMTD Digital Inc. (HKD) Stock Analysis: Exploring a 340.90% Revenue Growth in the Digital Landscape

AMTD Digital Inc. (NASDAQ: HKD), a dynamic player in the technology sector with its roots in the thriving software application industry, has been making waves in the digital world with..

Tvardi Therapeutics, Inc. (TVRD) Stock Analysis: A Biotech Contender with a 600% Potential Upside

Tvardi Therapeutics, Inc. (NASDAQ: TVRD) is capturing investor attention with its ambitious foray into the biotechnology sector, developing novel therapies targeting STAT3 for treating inflammatory and proliferative diseases. With a..

Erasca, Inc. (ERAS) Stock Analysis: A Biotech Gem with 72.9% Potential Upside

Erasca, Inc. (NASDAQ: ERAS), a clinical-stage biotechnology company, is garnering significant attention within the healthcare sector. With a market capitalization of $4.88 billion, Erasca is making notable strides in the..

Palvella Therapeutics, Inc. (PVLA)

⚠️ No article content returned.

..

Quantum-Si Incorporated (QSI) Stock Analysis: Exploring a Potential 203% Upside

As Quantum-Si Incorporated (NASDAQ: QSI) continues to innovate in the healthcare sector, investors are closely monitoring its stock performance, particularly given the potential upside of over 203% as suggested by..

Canopy Growth Corporation (CGC) Stock Analysis: Unpacking a 28.84% Potential Upside for Investors

Canopy Growth Corporation (NASDAQ: CGC), a prominent player in the cannabis industry, offers an intriguing opportunity for investors with a potential upside of 28.84%, according to recent analyst ratings. Despite..

Rigel Pharmaceuticals (RIGL) Stock Analysis: Navigating Biotech Challenges with a 30.90% Upside Potential

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) stands at a pivotal moment, capturing the attention of investors intrigued by the biotechnology sector’s volatile yet potentially rewarding nature. As of now, the stock..

aTyr Pharma, Inc. (ATYR) Stock Analysis: Exploring a 661.50% Potential Upside in the Biotech Sector

aTyr Pharma, Inc. (NASDAQ: ATYR), a clinical-stage biotechnology company based in San Diego, California, is capturing the attention of investors with a remarkable potential upside of 661.50%. Specializing in the..

Immutep Limited (IMMP) Stock Analysis: Exploring a Potential 463.70% Upside in the Biotech Sector

In the ever-evolving landscape of biotechnology, Immutep Limited (NASDAQ: IMMP) stands out with its ambitious portfolio of LAG-3 related immunotherapies aimed at tackling cancer and autoimmune diseases. With a modest..

ClearPoint Neuro Inc. (CLPT) Stock Analysis: Exploring a 56.98% Potential Upside in the Medical Devices Sector

ClearPoint Neuro Inc. (NASDAQ: CLPT) is a notable player in the healthcare sector, specifically within the medical devices industry. The company, with a market capitalization of approximately $456.65 million, is..

Fulcrum Therapeutics, Inc. (FULC) Stock Analysis: Navigating Volatility in Biotech Investments

Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a clinical-stage biopharmaceutical company, stands at the forefront of developing treatments for genetically defined diseases with high unmet medical needs. Based in Cambridge, Massachusetts, Fulcrum..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds